Company Announcements

HIGHLIGHTS:

• Net sales of $284.0 million, down 17% compared to prior year, primarily due to repositioning actions in Performance Chemicals, which included the exit of certain lower-margin end markets
• Net income of $20.5 million and diluted earnings per share (EPS) of $0.56 reflects before-tax special charges of $20.2 million; adjusted earnings of $36.4 million and diluted adjusted EPS of $0.99
• Adjusted EBITDA of $91.3 million increased 23% and adjusted EBITDA margin improved to 32.1% due primarily to the successful execution of repositioning actions in Performance Chemicals and continued strong profitability in Performance Materials
• Operating cash flow of $25.4 million with free cash flow of $15.4 million
• Ingevity widens its guidance range to reflect declines in industry forecasts of auto production due to trade tensions and tariff uncertainty; revised full year guidance of sales between $1.25 billion and $1.40 billion and adjusted EBITDA between $380 million and $415 million

The results and guidance in this release include non-GAAP financial measures. Refer to the section entitled “Use of non-GAAP financial measures” within this release. All comparisons are made versus the same period in 2024 unless otherwise stated.

NORTH CHARLESTON, S.C.--(BUSINESS WIRE)--May 5, 2025-- Ingevity Corporation (NYSE: NGVT) today reported its financial results for the first quarter of 2025.

First quarter net sales of $284.0 million declined 17%, primarily due to lower sales in the Industrial Specialties product line as a result of the strategic repositioning of the Performance Chemicals segment, which included the exit of certain lower-margin end markets, and lower sales in the Advanced Polymer Technologies segment.

Net income of $20.5 million and diluted earnings per share (EPS) of $0.56 reflect before-tax special charges of $20.2 million, primarily related to restructuring expenses associated with the repositioning actions. Adjusted earnings were $36.4 million and diluted adjusted EPS was $0.99. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) was $91.3 million, an increase of 23%, with adjusted EBITDA margin of 32.1%. The EBITDA improvement is primarily attributed to the Performance Chemicals segment, which has benefited from reduced raw material costs and improved product mix as a result of successful repositioning actions.

“This quarter’s strong results highlight the successful execution of the repositioning of our Performance Chemicals segment as well as the continued strength of our Performance Materials segment,” said David Li, Ingevity president and CEO. “I am honored to join Ingevity and energized by the opportunity to lead this world-class specialty materials company. Our focus will remain on portfolio optimization as we pursue best-in-class profitability in order to deliver superior stockholder returns.”

Performance Materials

Sales in Performance Materials rose 1% to $146.8 million primarily due to higher volume in China and the Asia Pacific region. North America’s improved mix of more fuel-efficient vehicles, which utilize higher value product, offset lower volume in the region. Segment EBITDA was $79.1 million, up 1%, and segment EBITDA margins were 53.9%.

Advanced Polymer Technologies

Sales in Advanced Polymer Technologies were down approximately $6 million, or 12%, to $42.2 million as higher volumes in the EMEA region and North America were offset by lower volumes in Asia. Segment EBITDA increased $3.0 million to $12.5 million, with segment EBITDA margin increasing to 29.6%. The EBITDA increase was driven primarily by higher utilization rates as we built inventory in preparation for a planned extended outage in the second quarter to install new boilers.

Performance Chemicals

Sales in Performance Chemicals were $95.0 million, down 35%. Industrial Specialties product line sales of $50.7 million were down 50% due primarily to the impact of repositioning actions implemented during 2024 that led to the exit of certain lower-margin end markets. Road Technologies product line sales were $44.3 million, down $1.4 million. Segment EBITDA was negative $0.3 million, an improvement of $10.3 million, reflecting the successful execution of repositioning actions, which included benefits from cost savings actions, improved product mix from the exit of certain lower-margin end markets, and lower raw material costs.

Liquidity/Other

Operating cash flow was $25.4 million with free cash flow of $15.4 million, reflecting improved working capital due to lower raw material costs and disciplined capital spend. There were no share repurchases for the quarter and $353.4 million remains available under the current $500 million Board authorization. Net leverage improved from last quarter to 3.3 times.

Full Year 2025 Guidance

“As we continue to execute on our strategic commitments of improving profitability and reducing leverage, our strong market positions and global manufacturing footprint give us the flexibility to withstand certain market disruptions. However, the current state of international trade relations has lowered expectations of global auto production, and therefore we are widening the range of our guidance to reflect this risk. Our revised guidance is sales between $1.25 billion and $1.40 billion and adjusted EBITDA of between $380 million and $415 million,” said Li.

Additional Information

The company will host a live webcast on Tuesday, May 6, at 9:00 a.m. (Eastern) to discuss Ingevity’s first quarter fiscal results. The webcast can be accessed here or on the investors section of Ingevity’s website. You may also listen to the conference call by dialing 833 470 1428 (inside the U.S.) and entering access code 815699. Callers outside the U.S. can find global dial-in numbers here. For those unable to join the live event, a recording will be available beginning at approximately 2:00 p.m. (Eastern) on May 6, 2025, through May 5, 2026, at this replay link .

Ingevity: Purify, Protect and Enhance

Ingevity provides products and technologies that purify, protect and enhance the world around us. Through a team of talented and experienced people, we develop, manufacture and bring to market solutions that help customers solve complex problems and make the world more sustainable. We operate in three reporting segments: Performance Materials, which includes activated carbon; Advanced Polymer Technologies, which includes caprolactone polymers; and Performance Chemicals, which includes specialty chemicals and road technologies. Our products are used in a variety of demanding applications, including adhesives, agrochemicals, asphalt paving, bioplastics, coatings, elastomers, lubricants, paint for road markings, oil drilling, and automotive components. Headquartered in North Charleston, South Carolina, Ingevity operates from 24 locations around the world and employs approximately 1,600 people. The company’s common stock is traded on the New York Stock Exchange (NYSE:NGVT). For more information, visit ingevity.com.

Use of non-GAAP financial measures: This press release includes certain non‐GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. Reconciliations of non‐GAAP financial measures to GAAP financial measures are provided within the Appendix to this press release. Investors are urged to consider carefully the comparable GAAP measures and the reconciliations to those measures provided. The company does not attempt to provide reconciliations of forward-looking non-GAAP guidance to the comparable GAAP measure because the impact and timing of the factors underlying the guidance assumptions are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, Ingevity believes such reconciliations would imply a degree of certainty that could be confusing to investors.

Forward-looking statements: This press release contains “forward looking statements” within the meaning of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements generally include the words “will,” “plans,” “intends,” “targets,” “expects,” “outlook,” “guidance,” “believes,” “anticipates” or similar expressions. Forward looking statements may include, without limitation, anticipated timing, results, charges and costs of any current or future repositioning of our Performance Chemicals segment, including the announced review of strategic alternatives for the Industrial Specialties product line and North Charleston, South Carolina crude tall oil refinery, the oleo-based product refining transition, closure of our plants in Crossett, Arkansas and DeRidder, Louisiana; leadership transitions within our organization; the potential benefits of any acquisition or investment transaction, expected financial positions, guidance, results of operations and cash flows; financing plans; business strategies and expectations; operating plans; capital and other expenditures; competitive positions; growth opportunities for existing products; benefits from new technology and cost reduction initiatives, plans and objectives; litigation-related strategies and outcomes; and markets for securities. Actual results could differ materially from the views expressed. Factors that could cause actual results to materially differ from those contained in the forward looking statements, or that could cause other forward looking statements to prove incorrect, include, without limitation, charges, costs or actions, including adverse legal or regulatory actions, resulting from, or in connection with, the current or future repositioning of our Performance Chemicals segment, including the announced review of strategic alternatives for the Industrial Specialties product line and North Charleston, South Carolina crude tall oil refinery, the oleo-based product refining transition, closure of our plants in Crossett, Arkansas and DeRidder, Louisiana; losses due to resale of crude tall oil at less than we paid for it; leadership transitions within our organization; adverse effects from general global economic, geopolitical and financial conditions beyond our control, including inflation, global trade tensions, and the Russia Ukraine war and conflict in the middle east; risks related to our international sales and operations; adverse conditions in the automotive market; competition from substitute products, new technologies and new or emerging competitors; worldwide air quality standards; a decrease in government infrastructure spending; adverse conditions in cyclical end markets; the limited supply of or lack of access to sufficient raw materials, or any material increase in the cost to acquire such raw materials; issues with or integration of future acquisitions and other investments; the provision of services by third parties at several facilities; supply chain disruptions; natural disasters and extreme weather events; or other unanticipated problems such as labor difficulties (including work stoppages), equipment failure or unscheduled maintenance and repair; planned and unplanned production slowdowns and shutdowns, turnarounds and outages, attracting and retaining key personnel; dependence on certain large customers; legal actions associated with our intellectual property rights; protection of our intellectual property and other proprietary information; information technology security breaches and other disruptions; complications with designing or implementing our new enterprise resource planning system; government policies and regulations, including, but not limited to, those affecting the environment, climate change, tax policies, tariffs and the chemicals industry; losses due to lawsuits arising out of environmental damage or personal injuries associated with chemical or other manufacturing processes; and the other factors detailed from time to time in the reports we file with the Securities and Exchange Commission (the “SEC”), including those described in Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10 K as well as in our other filings with the SEC. These forward-looking statements speak only to management’s beliefs as of the date of this press release. Ingevity assumes no obligation to provide any revisions to, or update, any projections and forward-looking statements contained in this press release.

Ingevity Corporation

Non-GAAP Financial Measures

Ingevity has presented certain financial measures, defined below, which have not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and has provided a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP on the following pages. These financial measures are not meant to be considered in isolation nor as a substitute for the most directly comparable financial measure calculated in accordance with GAAP. Investors should consider the limitations associated with these non-GAAP measures, including the potential lack of comparability of these measures from one company to another.

We believe these non-GAAP financial measures provide management as well as investors, potential investors, securities analysts, and others with useful information to evaluate the performance of the business, because such measures, when viewed together with our financial results computed in accordance with GAAP, provide a more complete understanding of the factors and trends affecting our historical financial performance, liquidity measures, and projected future results.

Ingevity uses the following non-GAAP measures:

Adjusted earnings (loss) is defined as net income (loss) plus restructuring and other (income) charges, net, goodwill impairment charge, acquisition and other-related (income) costs, pension and postretirement settlement and curtailment (income) charges, loss on CTO resales, CTO supply contract termination charges, (gain) loss on strategic investments, debt refinancing fees, litigation verdict charges, proxy contest charges, and the income tax expense (benefit) on those items, less the provision (benefit) from certain discrete tax items.

Diluted adjusted earnings (loss) per share is defined as diluted earnings (loss) per common share plus restructuring and other (income) charges, net, per share, goodwill impairment charge per share, acquisition and other-related (income) costs per share, pension and postretirement settlement and curtailment (income) charges per share, loss on CTO resales per share, CTO supply contract termination charges per share, (gain) loss on strategic investments per share, debt refinancing fees per share, litigation verdict charge per share, proxy contest charges per share and the income tax expense (benefit) per share on those items, less the provision (benefit) from certain discrete tax items per share.

Adjusted EBITDA is defined as net income (loss) plus interest expense, net, provision (benefit) for income taxes, depreciation, amortization, restructuring and other (income) charges, net, goodwill impairment charge, acquisition and other-related (income) costs, litigation verdict charges, (gain) loss on strategic investments, loss on CTO resales, CTO supply contract termination charges, proxy contest charges, and pension and postretirement settlement and curtailment (income) charges, net.

Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Net sales.

Free Cash Flow is defined as the sum of net cash provided by (used in) the following items: operating activities less capital expenditures.

Net Debt is defined as the sum of notes payable, short-term debt, current maturities of long-term debt and long-term debt including finance lease obligations less the sum of cash and cash equivalents, restricted cash associated with our new market tax credit financing arrangement, and restricted investment associated with certain finance lease obligations, excluding the allowance for credit losses on held-to-maturity debt securities held within the restricted investment.

Net Debt Ratio is defined as Net Debt divided by the last twelve months Adjusted EBITDA, inclusive of acquisition-related pro forma adjustments.

Ingevity's management also uses the above financial measures as the primary measures of profitability and liquidity of the business. In addition, Ingevity believes Adjusted EBITDA and Adjusted EBITDA Margin are useful measures because they exclude the effects of financing and investment activities as well as non-operating activities.

GAAP Reconciliation of 2025 Adjusted EBITDA Guidance

A reconciliation of net income to adjusted EBITDA as projected for 2025 is not provided. Ingevity does not forecast net income as it cannot, without unreasonable effort, estimate or predict with certainty various components of net income. These components, net of tax, include further restructuring and other income (charges), net; additional acquisition and other-related (income) costs; litigation verdict charges; additional pension and postretirement settlement and curtailment (income) charges; and revisions due to legislative tax rate changes. Additionally, discrete tax items could drive variability in our projected effective tax rate. All of these components could significantly impact such financial measures. Further, in the future, other items with similar characteristics to those currently included in adjusted EBITDA, that have a similar impact on the comparability of periods, and which are not known at this time, may exist and impact adjusted EBITDA.

INGEVITY CORPORATION

Reconciliation of Non-GAAP Financial Measures

View source version on businesswire.com: https://www.businesswire.com/news/home/20250505151001/en/

Caroline Monahan
843-740-2068
media@ingevity.com

Investors:
John E. Nypaver, Jr.
843-740-2002
investors@ingevity.com

Source: Ingevity Corporation